par Cortes, Javier;Vahdat, L.;Blum, J.;Twelves, Chris J;Campone, M.;Roche, Henri;Bachelot, Thomas;Awada, Ahmad ;Paridaens, R. ;Goncalves, A.;Shuster, D.;Wanders, Jantien;Fang, F.;Gurnani, R.;Richmond, E.;Cole, Patricia E;Ashworth, Simon;Allison, M.
Référence Journal of clinical oncology, 28, 25, page (3922-3928)
Publication Publié, 2010-09
Référence Journal of clinical oncology, 28, 25, page (3922-3928)
Publication Publié, 2010-09
Article révisé par les pairs
Résumé : | The activity and safety of eribulin mesylate (E7389), a nontaxane microtubule dynamics inhibitor with a novel mechanism of action, were evaluated in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, taxane, and capecitabine. |